Skip to main content
HighlightsHighlights Archive

Media Monitoring: 15 – 21 January 2022

By January 21, 2022No Comments

Pressure leads GPs to increase antibiotic prescribing

  • The pressure GPs are working under has been linked to increasing broad-spectrum antibiotic prescribing in England by health economists at The University of Manchester and University of Southern Denmark
  • The association, say the team, means that pressure on GPs could contribute to antimicrobial resistance

NHS pilots genetic testing to predict risk of heart disease

  • A world-first pilot of predictive genetic testing aiming to identify those at high risk of cardiovascular disease is under way in GP surgeries in the north of England
  • The NHS pilot, called Heart, is offering genetic tests to 1,000 healthy volunteers aged between 45 and 64 years old to give more accurate predictions for their risk of heart disease and stroke 

NHS cancer checks at record high with quarter of a million in one month

  • The figures show that 246,000 people were checked for cancer in November – three times as many compared to the beginning of the pandemic in April 2020, when people were reluctant to come forward
  • Monthly figures also show that more than nine in ten people received their first treatment within a month – a standard that has not dipped below 90% throughout the pandemic despite the NHS treating more than half a million COVID patients and delivering 114 million vaccinations to date

Professor Sir Jonathan Van-Tam to leave DCMO role in Spring 2022

  • Professor Van-Tam who joined DHSC on secondment from the University of Nottingham in 2017 will return to be the Pro-Vice-Chancellor for Faculty of Medicine and Health Sciences
  • As the DCMO for Health Protection, Professor Van-Tam has played important roles in a number of different incidents

NICE to approve changes for NHS technology evaluation

  • The National Institute for Health and Care Excellence (NICE) is committed to greater flexibility in its evaluation process of new and promising health technologies
  • These will give patients earlier access to innovative new treatments by allowing greater flexibility over ‘value for money’ discussions
  • They will also consider a broader evidence base, provide more transparency and enable faster decision-making for NICE’s independent committees

Guardant enrols first patient in SHIELD lung study

  • Guardant Health’s latest liquid biopsy test is delving deep into lung cancer detection. The Redwood City, CA-based company has enrolled the first patient in the Screening for HIgh-frEquency maLignant Disease (SHIELD) LUNG study, a nearly 10,000-patient prospective, registrational trial
  • The company said the study will evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50 to 80. It will run in 100 centers in the U.S. and Europe